1. Home
  2. SAR vs HELP Comparison

SAR vs HELP Comparison

Compare SAR & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saratoga Investment Corp New

SAR

Saratoga Investment Corp New

HOLD

Current Price

$22.20

Market Cap

372.7M

Sector

Finance

ML Signal

HOLD

HELP

Cybin Inc. Common Stock

N/A

Current Price

$4.87

Market Cap

281.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SAR
HELP
Founded
2007
N/A
Country
United States
Canada
Employees
N/A
50
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
372.7M
281.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SAR
HELP
Price
$22.20
$4.87
Analyst Decision
Hold
Strong Buy
Analyst Count
4
1
Target Price
$23.75
$95.00
AVG Volume (30 Days)
126.6K
1.0M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
14.48%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.39
N/A
P/E Ratio
$9.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$21.10
$5.09
52 Week High
$25.64
$8.55

Technical Indicators

Market Signals
Indicator
SAR
HELP
Relative Strength Index (RSI) 32.07 35.35
Support Level $21.40 N/A
Resistance Level $23.47 $7.28
Average True Range (ATR) 0.55 0.65
MACD -0.14 -0.24
Stochastic Oscillator 0.00 1.31

Price Performance

Historical Comparison
SAR
HELP

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.

Share on Social Networks: